Format

Send to

Choose Destination
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 1;1032:119-130. doi: 10.1016/j.jchromb.2016.04.040. Epub 2016 Apr 27.

Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine.

Author information

1
Research Institute for Chromatography, President Kennedypak 26, B-8500 Kortrijk, Belgium. Electronic address: koen.sandra@richrom.com.
2
Research Institute for Chromatography, President Kennedypak 26, B-8500 Kortrijk, Belgium.
3
Agilent Technologies, 2850 Centerville Rd, Wilmington, DE 19808, USA.

Abstract

Antibody-drug conjugates might be the magic bullets referred to by Paul Ehrlich over 100 years ago. Together with a huge therapeutic potential, these molecules come with a structural complexity that drives state-of-the-art chromatography and mass spectrometry to its limits. The use of multiple heart-cutting (mLC-LC) and comprehensive (LC×LC) multidimensional LC in combination with high resolution mass spectrometry for the characterization of the lysine conjugated antibody-drug conjugate ado-trastuzumab emtansine, commercialized as Kadcyla, is presented. By combining protein and peptide measurements, attributes such as drug loading, drug distribution and drug conjugation sites can be assessed in an elegant manner.

KEYWORDS:

Ado-trastuzumab emtansine; Antibody-drug conjugate; Comprehensive; Multiple heart-cutting; Two-dimensional liquid chromatography

PMID:
27160547
DOI:
10.1016/j.jchromb.2016.04.040
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center